Source: Geron Corporation
Posted: June 11, 2007 07:30 AM EDT
Summary:
In an official company news release, Geron Corporation (Nasdaq:GERN) today announced the presentation of research studies indicating that GRNOPC1, the company’s human embryonic stem cell (hESC)-based therapeutic for the treatment of spinal cord injury, evades a direct attack by the human immune system. The findings could mean that patients treated with GRNOPC1 would require significantly lower doses and/or shorter courses of immunosuppression than what are required for patients who undergo solid organ transplants.
